Medicare Benefits Schedule - Item 16060

¹⁷⁷Lutetium-DOTA-somatostatin receptor agonist treatment cycle for patients with histologically confirmed and inoperable neuroendocrine neoplasm (NEN), either locally advanced or metastatic, with documented disease progression or uncontrolled symptoms related to their NEN despite standard therapy who:
     a) have high tumour somatostatin receptor expression demonstrated on whole body 68Ga DOTA somatostatin agonist PET study; and
     b) are considered suitable for a course of 177Lutetium-DOTA-somatostatin receptor agonist therapy by a formally convened NEN      multidisciplinary board.

Includes the necessary patient preparation, administration and treatment, immediate patient aftercare required for the treatment cycle, consultation with the supervising specialist within 36 hours of treatment, and a post-infusion SPECT if performed.

Fee: $9,999.95 Benefit: 75% = $7,500.00 85% = $9,895.45

(See para TR.3.1 of explanatory notes to this Category)

• Previous - Item 16055
• Next - Item 16400

Medicare benefits for items in Group T3 are only payable when the service is provided by a specialist or consultant physician with training in nuclear medicine.

Related Items: 16003 16006 16009 16012 16015 16018 16050 16055 16060